Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin

ABSTRACT Background The purpose of this study was to present our evaluation of the outcomes of concurrent chemoradiotherapy (CRT) in patients with locally advanced cutaneous squamous cell carcinoma (SCC). Methods This was a prospective phase II study. The primary endpoint was complete response (CR)....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Head & neck 2017-04, Vol.39 (4), p.679-683
Hauptverfasser: Nottage, Michelle K., Lin, Charles, Hughes, Brett G. M., Kenny, Lizbeth, Smith, David D., Houston, Kathleen, Francesconi, Alessandra
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Background The purpose of this study was to present our evaluation of the outcomes of concurrent chemoradiotherapy (CRT) in patients with locally advanced cutaneous squamous cell carcinoma (SCC). Methods This was a prospective phase II study. The primary endpoint was complete response (CR). Patients with locally/regionally advanced cutaneous SCC deemed unsuitable for surgery received definitive radiotherapy (RT; 70 Gy in 35fractions) and concurrent weekly platinum‐based chemotherapy (cisplatin 40 mg/m2 or carboplatin area under the curve 2). Results Twenty‐one patients were enrolled in this study. Eighteen patients had a locally advanced primary or nodal disease in the head and neck region with 66% having stage IV nonmetastatic disease. Of 19 evaluable patients, 10 achieved a CR to definitive CRT with 2 further patients rendered disease‐free by salvage surgery for an overall CR of 63%. Conclusion This is the only prospective series of CRT for cutaneous SCC. A high CR rate was documented in patients with locoregional advanced disease who were unable to undergo surgery. © 2016 Wiley Periodicals, Inc. Head Neck 39: 679–683, 2017
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.24662